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Abstract
Background: The effects of left ventricular (LV) diastolic function are well known in cardiac surgery, 
but unclear in transcatheter aortic valve implantation (TAVI). The objective of this study was to exam-
ine the association of preoperative LV diastolic function with medium to long-term outcomes of TAVI.
Methods: Eighty patients who underwent TAVI were classified into grades I, II and III based on pre-
operative LV diastolic function. Findings related to cardiovascular outcomes after TAVI were extracted 
retrospectively from clinical and echocardiographic data and relationships with diastolic function were 
examined.
Results: The average follow-up was 529 days (interquartile range {IQR] 358–741 days). Cardiovascu-
lar events occurred in 17 cases, including 6 deaths, and were significantly associated with Euro II score 
(p = 0.043), albumin level (p = 0.026), coronary artery disease (CAD) (p = 0.017), and diastolic func-
tion (p < 0.001). The 360-day event-free rates were 89.5%, 89.5% and 37.5% for grades I, II and III  
(p = 0.00013). Median event-free survival (EFS) in grade III cases was 180 days. In a Cox propor-
tional hazard model, LV diastolic dysfunction (hazard ratio [HR] 3.99, 95% confidence interval [CI] 
1.35–11.80, p = 0.012) and low albumin (HR 4.73, 95% CI 1.42–15.80, p = 0.012) were significant 
independent predictors of reduced EFS.
Conclusions: Medium to long-term outcomes of TAVI were poorer in patients with deteriorated LV 
diastolic function, and outcomes in grade III cases were significantly worse than those in grade I and II 
cases. Preoperative LV diastolic function may be useful in prediction of outcomes after TAVI. (Cardiol 
J 2019; 26, 1: 29–35)
Key words: left ventricular diastolic function, aortic stenosis, transcatheter aortic valve 
implantation (TAVI), outcomes, prognosis, echocardiography
Introduction
Some cases of aortic stenosis (AS) are inoper-
able due to underlying disease, severity and frailty 
[1–3]. In these cases, the increasingly common use 
of transcatheter aortic valve implantation (TAVI) 
may improve prognosis [1, 4]. An increase in AS-
-induced afterload causes reduced left ventricular 
(LV) compliance, and elevated LV end-diastolic 
pressure causes reduced diastolic function, which 
are causes of a poor prognosis. TAVI reduces the 
transaortic gradient and relieves afterload, with 
a resultant improvement in systolic and diastolic 
function [1, 4–13]. However, the effects of LV diastolic 
dysfunction on prognosis after TAVI have not been 
examined. Therefore, the objective of this study was 
to analyze prognosis based on preoperative LV dias-
tolic function in patients treated with TAVI.
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Methods
Patient population
A retrospective observational study was con-
ducted in 80 patients who were diagnosed with 
severe AS and underwent TAVI at Teikyo Univer-
sity Hospital from February 2014 to August 2015. 
The exclusion criteria included shock, emergency 
surgery, chronic atrial fibrillation (AF), severe mi-
tral annular calcification, moderate to severe mitral 
stenosis, and severe mitral regurgitation. Patient 
background, clinical findings and blood test results 
were retrieved from electronic medical records 
(EMRs) and anesthesia charts. Data were collected 
for age, gender, European System for Cardiac 
Operative Risk Evaluation II (Euro II) score [5], 
Logistic Euro (Log Euro) score, Society of Tho-
racic Surgery (STS) score [6], albumin level [7], 
renal function based on estimated glomerular 
filtration rate (eGFR), hypertension, diabetes, 
dyslipidemia, coronary artery disease (CAD) and 
percutaneous coronary intervention, chronic ob-
structive pulmonary disease, and New York Heart 
Association classification.
Echocardiographic variables
The following echocardiographic findings were 
obtained from EMRs: LV ejection fraction (LVEF), 
E/e’, septal e’, lateral e’, tricuspid regurgitation (TR) 
velocity, left atrial volume index (LAVI), pulmo-
nary veins: systolic velocity/diastolic velocity 
ratio (S/D ratio) and time difference between 
duration of pulmonary vein flow and mitral inflow 
during atrial contraction (Ar-A duration). Echo-
cardiography was performed following American 
Society of Echocardiography (ASE) guidelines [14, 
15]. Preoperative LV diastolic dysfunction was 
classified into three grades (I, II, and III) based 
on 2016 ASE Recommendations for Evaluation of 
Left Ventricular Diastolic Function by Echocar-
diography [16]. For subjects at the borderline of 
grades I and II who were difficult to classify with 
the algorithm, left atrial pressure was assessed 
with LAVI, S/D ratio and Ar-A duration for clas-
sification into grades. Echocardiography in all 
subjects was performed by two cardiologists at 
our hospital. In all cases, echocardiography was 
performed once several days before TAVI subse-
quent to admission to hospital.
Endpoints
The endpoints of the study were cardiovas-
cular (CV) events during the follow-up period 
after discharge, and mortality. The incidences of 
events on days 180, 360 and 540 were examined. 
The study was approved by the research ethics 
committee of the documented hospital. The study 
protocol conforms to the ethical guidelines of the 
1975 Declaration of Helsinki. Exacerbation of heart 
failure, shift to AF, pneumonia and events including 
conduction block.
Statistical analysis
Statistical analyses were performed with EZR 
(Saitama Medical Center, Jichi Medical University, 
Saitama, Japan), which is a graphical user interface 
for R (The R Foundation for Statistical Comput-
ing, Vienna, Austria). Continuous variables are 
expressed as mean ± standard deviation and were 
compared by unpaired t test or one-way analy-
sis of variance (ANOVA). Categorical variables 
are expressed as frequencies (percentages) and 
compared by the Fisher exact test. Time-to-event 
analysis was performed using the Kaplan-Meier 
method and compared between groups by log-rank 
test. Cox proportional hazards models with best 
subset regression were used to identify clinical 
and echocardiographic measurements that were 
significantly related to cardiac events or death 
during follow-up. A p value < 0.05 was considered 
significant in all analyses.
Results
Patient characteristics
The preoperative patient background is shown 
in Table 1. The mean age was 85.0 ± 5.2 years old 
and 77.5% of the subjects were female. Euro II, 
LogEuro and STS scores were 5.9 ± 4.6, 18.4 ± 
± 9.7 and 8.1 ± 3.8, respectively, and LVEF, E/e’ 
and LAVI were 57.5 ± 10.8%, 21.8 ± 8.6 and 63.5 ± 
± 25.1 mL/m2, respectively. There were no signifi-
cant differences in age, gender, Euro II, LogEuro, 
STS, albumin or underlying disease, except for 
eGFR, CV events, E/e’ and LAVI, among patients 
with LV diastolic dysfunction of grades I, II, and III 
(Table 2).
Grade classification
In preoperative echocardiography, LVEF, E/e’, 
LAVI, S/D ratio and Ar-A duration, but not TR 
velocities, were measured in all subjects. The 
grade classification was performed based on the 
algorithm of the 2016 ASE Recommendations for 
the Evaluation of Left Ventricular Diastolic Func-
tion by Echocardiography three subjects however, 
were difficult to classify and were placed into grade 
I or II (grade I: 2, grade II: 1) by assessing left 
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atrial pressure in accordance with LAVI, S/D and 
Ar-A duration.
Complications during TAVI
Complications developing during TAVI included 
hemorrhage from a puncture site in 2 patients; femo-
ral artery occlusion, oozing from the left ventricle 
after TAVI, mitral valve prolapse, cardiac tamponade 
after TAVI, right ventricular injury caused by a pac-
ing wire, and stenosis due to calcified plaque in the 
entrance of the left coronary artery after TAVI in 
1 patient and complete atrioventricular block after 
TAVI in 4 patients. No patients died during surgery 
and the follow-up survey after discharge from hos-
pital was conducted in all subjects.
Cardiovascular events
The average follow-up was 529 days (inter-
quartile range [IQR] 358–741 days). Cardiovascu-
lar events during follow-up occurred in 17 of 80 
subjects, and were exacerbated  by heart failure 
in all 17 subjects. Of these subjects, 4 developed 
heart failure with AF. Onset of heart failure with 
AF was defined as CV events when NT-pro–B-type 
natriuretic peptide was higher during the observa-
tion of period after discharge than that at the time 
of  discharge and the patients had clinical symptoms 
including dyspnea and pedal edema, consequently, 
they were diagnosed with AF-induced heart failure. 
Heart failure was the cause of death in all 6 sub-
jects who died (grade I: 1, grade II: 5, grade III: 0). 
Table 1. Baseline characteristics of 80 patients in this study. 
Variables Overall  
(n = 80)
Event-free survival  
(n = 63)
Cardiovascular events 
(n = 17)
P
Age [years] 85.0 ± 5.2 85.3 ± 4.8 83.9 ± 6.3 0.3
Female 62 （77.5） 48 (76.2%) 14 (82.4%) 0.75
Euro II 5.9 ± 4.6 5.4 ± 4.2 7.9 ± 5.8 0.043
LogEuro 18.4 ± 9.7 17.8 ± 9.5 20.7 ± 10.3 0.28
STS 8.1 ± 3.8 7.9 ± 3.7 8.8 ± 4.2 0.36
Albumin 3.7 ± 0.5 3.7 ± 0.4 3.5 ± 0.6 0.026
eGFR 50.2 ± 17.0 51.0 ± 17.1 47.5 ± 16.6 0.46
Hypertension 60 (75%) 45 (71.4%) 15 (88.2%) 0.21
Diabetes mellitus 18 (22.5%) 15 (23.8%) 3 (17.6%) 0.75
Dyslipidemia 47 (58.8%) 37 (58.7%) 10 (58.8%) 1
Coronary artery disease 12 (15.0%) 6 (9.5%) 6 (35.2%) 0.017
Previous PCI 26 (32.5%) 18 (31.0%) 8 (36.4%) 0.16
COPD 13 (16.3%) 10 (15.8%) 3 (17.6%) 1
Class NYHA:
I None None None
II 33 (41.3%) 29 4
III 35 (43.8%) 27 8
IV 12 (15.0%) 7 5
Class NYHA III–IV 47 (58.8%) 34 (54.0%) 13 (76.5%) 0.11
Diastolic dysfunction:
Grade I 19 (23.8%) 17 2
Grade II 49 (61.3%) 41 8
Grade III 12 (15.0%) 5 7
LVEF 57.5 ± 10.8 57.9 ± 10.2 56.1 ± 13.1 0.55
E/e’ 21.8 ± 8.6 22.3 ± 8.9 19.6 ± 7.1 0.29
LAVI 63.5 ± 25.1 61.0 ± 23.5 72.6 ± 28.5 0.093
Continuous variables are shown as mean ± standard deviation, and categorical variables as frequencies (%); Euro II — European System for 
Cardiac Operative Risk Evaluation Score II; LogEuro — Logistic Euro score; STS — Society of Thoracic Surgeons score; eGFR — estimated 
glomerular filtration rate; PCI — percutaneous coronary intervention; COPD — chronic obstructive pulmonary disease; NYHA — New York 
Heart Association; LVEF — left ventricular ejection fraction; LAVI — left atrial volume index
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Non-CV events after discharge included pneumonia 
and 3-degree block (after 314 days) in 1 subject 
each and there were no deaths.
Some patients did not undergo echocardiography 
because they could not visit the hospital due to being 
elderly or having to travel a long distance, and some 
were excluded from follow-up due to CV events dur-
ing follow-up after TAVI. In the survey of prognoses, 
no patient was lost to follow-up because prognoses 
were determined by interview when visiting the hos-
pital or telephone calls to patients or their families.
Albumin (3.5 ± 0.6 vs. 3.7 ± 0.4 g/dL, p = 
= 0.026), Euro II score (7.8 ± 5.8 vs. 5.4 ± 4.2, 
p = 0.043) and CAD (35.2% vs. 9.5%, p = 0.017) 
were significantly related to CV events (Table 1). In 
grades I, II and III, the 180-day event-free survival 
(EFS) rates were 89.5%, 89.5% and 46.9%, the 
360-day EFS rates were 89.5%, 89.5% and 37.5%, 
and the 540-day EFS rates were 89.5%, 82.3% and 
37.5%, respectively. In grade III cases, the median 
EFS was 180 days (Fig. 1) and the prognosis based 
on EFS rates which were significantly worse than 
for grades I and II (p = 0.00013). Events occurred 
more frequently in cases with lower albumin (< 3.6 
vs. ≥ 3.6 g/dL, p = 0.0012), and CAD(+) vs. 
CAD(–), p = 0.0049; Fig. 2).
Figure 1. Kaplan-Meier event-free survival (EFS) rates 
for patients with diastolic function of grade I (n = 19), 
grade II (n = 49), and grade III (n = 12). The grade III 
median EFS time was 180 days. In grades I, II and III, the 
EFS rates were 89.5%, 89.5%, and 46.9% at 180 days; 
89.5%, 89.5%, and 37.5% at 360 days; and 89.5%, 
82.3%, and 37.5% at 540 days, respectively.
Table 2. Baseline grades for severity of diastolic dysfunction. 
Variables Grade I (n = 19) Grade II (n = 49) Grade III (n = 12) P
Age [years] 85.9 ± 4.7 85.4 ± 4.7 82.2 ± 7.0 0.11
Female 13 (68.4%) 37 (75.5%) 12 (100%) 0.1
Euro II 5.8 ± 5.2 5.6 ± 4.1 7.3 ± 5.8 0.5
LogEuro 16.3 ± 8.4 19.3 ± 10.7 18.2 ± 6.9 0.53
STS 7.4 ± 3.1 8.3 ± 3.7 8.4 ± 5.2 0.69
Albumin 3.8 ± 0.3 3.7 ± 0.5 3.7 ± 0.6 0.73
eGFR 56.8 ± 19.0 49.8 ± 16.3 41.4 ± 12.2 0.044
Hypertension 14 (73.7%) 37 (75.5%) 9 (75.0%) 1
Diabetes mellitus 5 (26.3%) 12 (24.5%) 1 (8.3%) 0.51
Dyslipidemia 11 (57.9%) 27(55.1%) 9 (75.0%) 0.5
Coronary artery disease 3 (15.8%) 7 (14.3%) 2 (16.7%) 1
Previous PCI 7 (36.8%) 17 (34.7%) 2 (16.7%) 0.49
COPD 4 (21.1%) 9 (18.4%) 0 (0%) 0.29
Class NYHA III–IV 10 (52.6%) 26 (53.1%) 9 (75.0%) 0.4
Cardiovascular events 2 (10.5%) 8 (16.3%) 7 (58.3%) < 0.001
LVEF 58.9 ± 7.8 57.3 ± 11.8 56.3 ± 11.3 0.78
E/e’ 14.2 ± 4.8 23.9 ± 8.4 25.1 ± 6.9 < 0.001
LAVI 43.7 ± 13.8 65.3 ± 21.1 90.0 ± 29.5 < 0.001
Continuous variables are shown as mean ± standard deviation, and categorical variables as frequencies (%); Euro II — European System for 
Cardiac Operative Risk Evaluation Score II; LogEuro — Logistic Euro score; STS — Society of Thoracic Surgeons score; eGFR — estimated 
glomerular filtration; PCI — percutaneous coronary intervention; COPD — chronic obstructive pulmonary disease; NYHA — New York Heart 
Association; LVEF — left ventricular ejection fraction; LAVI — left atrial volume index
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Predictors of medium and long-term  
prognosis
In univariate analysis, LV diastolic dysfunction 
(hazard ratio [HR] 3.84, p = 0.0016), low albumin 
(< 3.6 g/dL) (HR 4.36, p = 0.0029), and CAD 
(HR 3.78, p = 0.0089) were associated with CV 
events or mortality. In multivariate Cox regression 
analysis, LV diastolic dysfunction (HR 3.99, p = 
= 0.012) and low albumin (HR 4.73, p = 0.012) 
were independent predictors of a poor outcome 
during the follow-up period (Table 3).
Discussion
Technical improvements and advances in 
devices due to accumulated data have contributed 
to better outcomes of TAVI; however, problems 
remain regarding preoperative evaluation and 
postoperative complications. In this study, the rela-
tionship between preoperative LV diastolic function 
and postoperative complications in patients treated 
with TAVI was investigated. Pre-diastolic function 
grade was found to be strongly associated that 
a higher grade of preoperative LV diastolic dys-
function and with poorer EFS. Especially, events 
in grade III cases which occurred earlier and at 
a higher incidence than those for grades I and II. 
A Cox proportional hazards model indicated that 
preoperative LV function is an independent risk 
factor for postoperative CV events. Preoperative 
LV diastolic dysfunction has been shown to affect 
EFS after CV surgery [17]. TAVI is a brief and 
Table 3. Multivariate analysis of clinical and echocardiographic predictors of events.
Variables Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
Diastolic dysfunction 3.84 (1.66–8.84) 0.0016 3.99 (1.35–11.8) 0.012
Low albumin (< 3.6 g/dL) 4.36 (1.65–11.49) 0.0029 4.73 (1.42–15.8) 0.012
Coronary artery disease 3.78 (1.40–10.24) 0.0089
CI — confidence interval; HR — hazard ratio
Figure 2. Kaplan-Meier event free survival rates for cases with (A) albumin (Alb) < 3.6 g/dL vs. ≥ 3.6 g/dL, (B) CAD(+) 
vs. CAD(–); CAD — coronary artery disease.
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less invasive procedure that improves systolic 
and diastolic function at an earlier stage compared 
with surgical aortic valve replacement [4, 18]. The 
function of the LV system, including the left atrium, 
and right ventricular function recover early after 
TAVI and diastolic function is improved [4, 8], while 
AS-induced cardiac hypertrophy is improved over 
the medium to long-term, this further improves 
LV function [4, 13, 18, 19].
Albumin has been proposed to be a prognostic 
factor for postoperative mortality and complica-
tions [7, 20]. Yamamoto et al. [7] indicated that 
hypoalbuminemia was a predictor for mortality 
and complications after TAVI, and 30-day mortality 
was significantly higher in patients with albumin 
< 3.5 g/dL. The results of this study also showed 
that EFS after TAVI was significantly lower in 
subjects with albumin < 3.6 g/dL, which closely 
matches the results of Yamamoto et al. [7].
Of note is an algorithm proposed by Nagueh 
et al. [16] which was used for detection and sever-
ity classification of LV diastolic dysfunction into 
grades. This algorithm is simple to use for detec-
tion, but when the grade was difficult to determine 
because of the border zone (grade I or II), it was 
based on other echocardiographic findings, such 
as LAVI, S/D ratio and Ar-A duration. All subjects 
classified using other echocardiographic findings 
had no data for TR, due to a failure of TR velocity 
measurement. LAVI and S/D are related to mean 
left atrial pressure, and Ar-A duration is related to 
LV end-diastolic pressure [16]; therefore, increased 
left atrial pressure was assessed using these data 
and subjects were classified into grades I or II.
The most important finding in this study was 
that EFS rate in patients with preoperative LV 
diastolic dysfunction of grade III who were signifi-
cantly worse than those in patients with grades 
I and II. The median event occurrence period was 
180 days in grade III, which suggests that patients 
in grade III specially take care of follow-up after 
TAVI. Patients who complicate with CAD, which 
was found to be a risk factor in this study, may 
have further adverse outcomes. Use of TAVI has 
been slowly increasing, therefore some indices 
including LV diastolic function may be important 
for preoperative evaluation before TAVI.
Limitations of the study
The major limitations of the study were the 
retrospective observational design and the inclu-
sion of some subjects in whom detailed courses 
could not be followed for an extended period. The 
guidelines for LV diastolic function did not allow 
for some subjects to be classified into a grade using 
the algorithm alone. These subjects were classi-
fied by estimating increased left atrial pressure 
using other indicators; however, the accuracy of 
this method is unclear and the assigned grade is 
uncertain. Detailed courses were not found in all 
EMRs because elderly patients could not undergo 
echocardiography or a full interview during the 
observational period. In echocardiography, detailed 
data were available before TAVI, whereas postop-
erative data collected during follow-up had many 
missing values because some patients could not 
undergo echocardiography due to their condition. 
Consequently, changes in the grade of LV diastolic 
function from prior  to and after TAVI or postopera-
tive echocardiographic findings in follow up could 
not be verified. There was no postoperative mortal-
ity in 6 subjects in grade III, showing no tendency for 
worsening of outcomes at a higher grade. However, 
the number of subjects was insufficient to evaluate 
the significance of mortality data.  Euro II, LogEuro 
and STS scores were noted and used as indicators for 
preoperative risk assessment in CV surgery. In this 
study, significant differences in Euro II scores alone 
were found among cases with different LV diastolic 
dysfunction. Some studies indicate overestimation 
of these risk scores [21, 22], but it is unclear why 
only Euro II scores were significant in this study. 
However, it was noted that Euro II, LogEuro and 
STS scores are predictors of mortality risk after 
conventional CV surgeries, these scores may not 
be applicable to clinical status and performance of 
TAVI in extremely elderly patients.
Conclusions
Postoperative events after TAVI occurred 
more frequently in patients with advanced pre-
operative LV diastolic dysfunction, as found after 
other CV surgery. Events in cases with grade III 
LV diastolic dysfunction occurred earlier and at 
a significantly higher incidence than those in 
grades I and II. Therefore, diastolic function may be 
a useful indicator for prediction of outcomes after 
TAVI. A large-scale prospective study is required to 
validate these findings.  Present results show that 
postoperative outcomes after TAVI are influenced 
by several factors and these findings make the 
study particularly valuable in identifying patients 
who will benefit most from TAVI.
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